This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

John W. Williams, Jr, MD, MHS; Donald R. Holleman, Jr, MD; Greg P. Samsa, PhD; David L. Simel, MD, MHS

JAMA. 1995;273(13):1015-1021.

Abstract
Objective.
—To compare 14-day outcomes and relapse and recurrence rates among patients with acute maxillary sinusitis randomized to 3-day (3D) vs 10-day (10D) treatment with trimethoprim/sulfamethoxazole (TMP/SMX).

Setting.
—University-affiliated Veterans Affairs general medical and acute care clinics.

Patients.
—Consecutive patients with sinus symptoms and radiographic evidence of maxillary sinusitis (complete opacity, air-fluid level, or 6 mm of mucosal thickening). Patients were excluded for antibiotic use within the past week, TMP/ SMX allergy, symptoms for more than 30 days, or previous sinus surgery.

Methods.
—All subjects (n=80) received oxymetazoline nasal spray 0.05%, two sprays twice daily for 3 days. Subjects were randomly assigned to TMP/SMX double strength: one tablet twice daily for 10 days or one tablet twice daily for 3 days followed by 7 days of placebo. At 7 and 14 days, patients rated their overall sinus symptoms on a Likert scale. Radiographs were scored at baseline and 14 days by radiologists masked to clinical symptoms and treatment assignment. The primary outcome was number of days to "cure" or "much improvement" in sinus symptoms. Patients who were clinical successes by day 14 were assessed for symptomatic relapse or recurrence at 30 and 60 days, respectively.

Results.
—Groups were comparable at randomization: male, 100%; black, 53%; median age, 48 years (interquartile range, 41 to 63 years); symptom duration, 10 days (interquartile range, 6 to 17 days); bilateral maxillary disease, 51%; and radiograph score, 4 (interquartile range, 2 to 4). Outcome assessment was completed in 95% of patients at day 14 (n=76). Medication side effects and use of nonstudy sinus medications were equal between groups. By 14 days, 77% of 3D subjects and 76% of 10D subjects rated their sinus symptoms as cured or much improved (95% confidence interval for difference, -15% to 17%). Median days to cure/much improvement were 5.0 and 4.5 for the 3D and 10D groups, respectively; distributions of time to cure were not different (P=.34). Radiograph scores improved in both groups compared with baseline (2 points; P<.001), but improvement did not differ between groups (P=.31). Eight percent of 3D subjects and 13% of 10D subjects missed work due to sinus symptoms. Of the 52 patients who were clinical successes at 14 days and completed follow-up, three (11%) of 27 3D subjects and one (4%) of 25 10D subjects relapsed symptomatically by day 30; one (4%) of 27 3D subjects and one (4%) of 25 10D subjects suffered symptomatic recurrence between days 30 and 60 (P=.45 for the relapse and recurrence rates combined).

Conclusion.
—At the 2-week follow-up, clinical symptoms and radiograph scores improved equally following 3 or 10 days of TMP/SMX plus oxymetazoline nasal spray. Symptomatic relapse and recurrence were similar between groups. Three days of antibiotics were as effective as 10 days and, because of the high disease prevalence, hold the potential for substantial cost savings.

(JAMA. 1995;273:1015-1021)

Author Affiliations
From the Ambulatory Care Service and the Division of General Internal Medicine, Audie L. Murphy Memorial Veterans Hospital and the University of Texas Health Science Center at San Antonio (Dr Williams); Medical Service and the Division of General Internal Medicine, Lexington Veterans Hospital and the University of Kentucky, Lexington (Dr Holleman); and Health Services Research Field Program and the Division of General Internal Medicine, Durham Veterans Affairs Medical Center and Duke University Medical Center, Durham, NC (Drs Samsa and Simel).

Footnotes
Presented in part at the 17th annual meeting of the Society of General Internal Medicine, Washington, DC, April 28, 1994.

Reprint requests to Ambulatory Care Service (11C), Audie L. Murphy Memorial Veterans Hospital, 7400 Merton Minton Blvd, San Antonio, TX 78284 (Dr Williams).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Publication guidelines for quality improvement studies in health care: evolution of the SQUIRE project
Davidoff et al.
BMJ 2009;338:a3152-a3152.
ABSTRACT | FULL TEXT  

Publication Guidelines for Improvement Studies in Health Care: Evolution of the SQUIRE Project
Davidoff et al.
ANN INTERN MED 2008;149:670-676.
ABSTRACT | FULL TEXT  

Publication guidelines for quality improvement in health care: evolution of the SQUIRE project
Davidoff et al.
Qual Saf Health Care 2008;17:i3-i9.
ABSTRACT | FULL TEXT  

The SQUIRE (Standards for QUality Improvement Reporting Excellence) guidelines for quality improvement reporting: explanation and elaboration
Ogrinc et al.
Qual Saf Health Care 2008;17:i13-i32.
ABSTRACT | FULL TEXT  

Short-Duration Therapy for Respiratory Tract Infections
Goff
The Annals of Pharmacotherapy 2004;38:S19-S23.
ABSTRACT | FULL TEXT  

Acute Bacterial Sinusitis
Piccirillo
NEJM 2004;351:902-910.
FULL TEXT  

Comparison of Short-Course (5 Days) and Standard (10 Days) Treatment for Uncomplicated Cellulitis
Hepburn et al.
Arch Intern Med 2004;164:1669-1674.
ABSTRACT | FULL TEXT  

Modelling of escalating outpatient antibiotic expenditures
Zintzaras and Ioannidis
J Antimicrob Chemother 2003;52:1001-1004.
ABSTRACT | FULL TEXT  

Management of Acute and Chronic Sinusitis in Adult Patients
Conry and Castanheira
Journal of Pharmacy Practice 2003;16:335-348.
ABSTRACT  

Trimethoprim-Sulfamethoxazole Revisited
Masters et al.
Arch Intern Med 2003;163:402-410.
ABSTRACT | FULL TEXT  

Improving Reports of Studies of Diagnostic Tests: The STARD Initiative
Rennie
JAMA 2003;289:89-90.
FULL TEXT  

Physician Specialty Is Associated With Differences in the Evaluation and Management of Acute Bacterial Rhinosinusitis
Werning et al.
Arch Otolaryngol Head Neck Surg 2002;128:123-130.
ABSTRACT | FULL TEXT  

Impact of First-Line vs Second-Line Antibiotics for the Treatment of Acute Uncomplicated Sinusitis
Piccirillo et al.
JAMA 2001;286:1849-1856.
ABSTRACT | FULL TEXT  

CONSORT Revised--Improving the Reporting of Randomized Trials
Rennie
JAMA 2001;285:2006-2007.
FULL TEXT  

A 48-Year-Old Man With Recurrent Sinusitis
Kennedy
JAMA 2000;283:2143-2150.
FULL TEXT  

Penicillin for acute sore throat: randomised double blind trial of seven days versus three days treatment or placebo in adults
Zwart et al.
BMJ 2000;320:150-154.
ABSTRACT | FULL TEXT  

Are amoxycillin and folate inhibitors as effective as other antibiotics for acute sinusitis? A meta-analysis
de Ferranti et al.
BMJ 1998;317:632-637.
ABSTRACT | FULL TEXT  

Strategies for Stemming the Tide of Antimicrobial Resistance
Low and Scheld
JAMA 1998;279:394-395.
FULL TEXT  

A Clinical Trial of Hypertonic Saline Nasal Spray in Subjects With the Common Cold or Rhinosinusitis
Adam et al.
Arch Fam Med 1998;7:39-43.
ABSTRACT | FULL TEXT  

The Cost of Antibiotics in Treating Upper Respiratory Tract Infections in a Medicaid Population
Mainous III and Hueston
Arch Fam Med 1998;7:45-49.
ABSTRACT | FULL TEXT  

CONSORT statement on the reporting standards of clinical trials
Meade et al.
BMJ 1997;314:1126-1126.
FULL TEXT  

Ethical Decision Making in Managed Care
Sorum
Arch Intern Med 1996;156:2041-2045.
ABSTRACT  

A Double-Blind, Placebo-Controiled Trial of Decongestant-Antihistamine for the Treatment of Sinusitis in Children
Mccormick et al.
CLIN PEDIATR 1996;35:457-460.
ABSTRACT  

Improving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg et al.
JAMA 1996;276:637-639.
ABSTRACT  

How to Report Randomized Controlled Trials: The CONSORT Statement
Rennie
JAMA 1996;276:649-649.
ABSTRACT  

Bacteriology and {beta}-Lactamase Activity in Acute and Chronic Maxillary Sinusitis
Brook et al.
Arch Otolaryngol Head Neck Surg 1996;122:418-423.
ABSTRACT  

Meta-analysis of Randomized Controlled Trials: A Concern for Standards
Moher and Olkin
JAMA 1995;274:1962-1964.
ABSTRACT  

Three vs 10 Days of Trimethoprim/Sulfamethoxazole for Acute Maxillary Sinusitis
Rosborough and Rierach
JAMA 1995;274:1341-1341.
ABSTRACT  

Three vs 10 Days of Trimethoprim/Sulfamethoxazole for Acute Maxillary Sinusitis
Sawyer et al.
JAMA 1995;274:1341-1341.
ABSTRACT  

Three vs 10 Days of Trimethoprim/Sulfamethoxazole for Acute Maxillary Sinusitis
Shahar
JAMA 1995;274:1341-1341.
ABSTRACT  

Three-Day Therapy for Acute Sinusitis
Journal Watch Dermatology 1995;1995:16-16.
FULL TEXT  

THREE-DAY THERAPY FOR ACUTE SINUSITIS
JWatch General 1995;1995:1-1.
FULL TEXT  

Reporting Randomized Controlled Trials: An Experiment and a Call for Responses From Readers
Rennie
JAMA 1995;273:1054-1055.
ABSTRACT